Yahoo

Sanofi looks to widen Dupixent use to treat 'smoker's lung' after second trial win

(Reuters) -Sanofi plans to seek U.S. approval for its best-selling anti-inflammatory drug Dupixent to be used in the treatment of "smoker's lung", also known as COPD, after a second large trial showed ...

Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Regeneron Broadens Dupixent Use And Enters Radiopharmaceuticals With Telix

Regeneron Pharmaceuticals (NasdaqGS:REGN) and Sanofi secured European Commission approval for Dupixent in moderate to severe chronic spontaneous urticaria for children aged 2 to 11. The approval ...

Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)

Approval for children aged 2 to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the ...

Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria

Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous ...
JD Supra

Who Is Eligible to File a Dupixent Lymphoma Lawsuit? Understanding Criteria, Timing, and Next Steps

A diagnosis of T-cell lymphoma after using Dupixent raises serious questions for patients and families. Many want clear answers about whether they may have a legal claim and what criteria determine ...
Seeking Alpha

Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)

Dupixent has received regulatory approvals in one or more countries around the world for use in certain patients with atopic dermatitis, asthma, CRSwNP, EoE, prurigo nodularis, and CSU in different ...
Seeking Alpha

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP BP is a chronic, ...
WebMD

Dupixent: FDA Approves First Under-the-Skin Biologic Shot for Children Ages 2-11 Years With Chronic Hives Not Controlled With Antihistamines

What Is It, and Why Does It Matter? Dupixent (dupilumab) is a prescription biologic medicine given as an under‑the‑skin (subcutaneous) shot that helps reduce inflammation caused by certain immune ...